Skip to Main Content

Author Details

Jordi Rodon
The University of Texas MD Anderson Cancer Center
2006
241
53
Kirsten Obernier (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37972659Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.J Hepatol2024
36288393Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102).Clin Cancer Res2023
37561967Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.J Clin Oncol2023
37488446A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.Br J Cancer2023
37712875A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.Cancer Res Commun2023
37619847HER2-low expression in patients with advanced or metastatic solid tumors.Ann Oncol2023
37552839MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.Cancer Discov2023
37541280National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities.Lancet Oncol2023
37058010Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).Clin Cancer Res2023
37454202Actionability classification of variants of unknown significance correlates with functional effect.NPJ Precis Oncol2023
37388723Enhanced antiviral immunity and dampened inflammation in llama lymph nodes upon MERS-CoV sensing: bridging innate and adaptive cellular immune responses in camelid reservoirs.Front Immunol2023
37119590Limb-girdle myopathy and mild intellectual disability: The expanding spectrum of TANGO2-related disease.Neuromuscul Disord2023
37119430Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials.J Gastrointest Cancer2023
37311055A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.Oncologist2023
37237172Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.Br J Cancer2023
37072571Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.NPJ Precis Oncol2023
36751659Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.J Immunother Precis Oncol2023
36748086Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.iScience2023
36539183Arrhythmic risk in single or recurrent episodes of unexplained syncope with complete bundle branch block.Rev Esp Cardiol (Engl Ed)2023
36529447Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.Ann Oncol2023
36658425Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.Nat Med2023
36823022Extended Viral Shedding of MERS-CoV Clade B Virus in Llamas Compared with African Clade C Strain.Emerg Infect Dis2023
34593528High <i>FGFR1-4</i> mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer.Clin Cancer Res2022
35739576Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas.One Health Outlook2022
35834760Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers.JCO Precis Oncol2022
35821254Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.Cell Mol Immunol2022
36458182Agreement and differential use of laboratory methods for the detection and quantification of SARS-CoV-2 in experimentally infected animals.Front Microbiol2022
36146808Susceptibility of Domestic Goat (<i>Capra aegagrus hircus</i>) to Experimental Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.351/Beta Variant.Viruses2022
36039910A phase II study of TAS-117 in patients with advanced solid tumors harboring germline <i>PTEN</i>-inactivating mutations.Future Oncol2022
36302890Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.NPJ Precis Oncol2022
36167932Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and humoral responses against different variants of concern in domestic pet animals and stray cats from North-Eastern Spain.Transbound Emerg Dis2022
36056449Evaluation of alpaca tracheal explants as an ex vivo model for the study of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.Vet Res2022
34955064Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice.Vet Pathol2022
35012962Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.Life Sci Alliance2022
34918620Enhanced replication fitness of MERS-CoV clade B over clade A strains in camelids explains the dominance of clade B strains in the Arabian Peninsula.Emerg Microbes Infect2022
35282384Sex-Related Differences in Patients With Unexplained Syncope and Bundle Branch Block: Lower Risk of AV Block and Lesser Need for Cardiac Pacing in Women.Front Cardiovasc Med2022
35001773Middle East respiratory syndrome coronavirus infection in camelids.Vet Pathol2022
35332062IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.J Immunother Cancer2022
34904659Rapid SARS-CoV-2 Inactivation in a Simulated Hospital Room Using a Mobile and Autonomous Robot Emitting Ultraviolet-C Light.J Infect Dis2022
35233547Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.Cell Rep Med2022
35231500Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.Antiviral Res2022
35108036Clinical and Molecular Characterization of <i>POLE</i> Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.JCO Precis Oncol2022
34661906Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified.Cancer2022
34839786Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands.Emerg Microbes Infect2022
32439473Syncope in Patients With Severe Aortic Stenosis: More Than Just an Obstruction Issue.Can J Cardiol2021
35663531Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens.J Immunother Precis Oncol2021
36569267Cardiac biometric variables and arrhythmic events during COVID-19 pandemic lockdown in patients with an implantable cardiac monitor for syncope work-up.Med Clin (Engl Ed)2021
33825619Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster.Emerg Microbes Infect2021
33510275SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity.Sci Rep2021
33642036[Cardiac biometric variables and arrhythmic events during COVID-19 pandemic lockdown in patients with an implantable cardiac monitor for syncope work-up].Med Clin (Barc)2021
  • 1 - 50 of 241

Recommended Authors

Felipe Batalini
Mayo Clinic Arizona
Career Start Year 2015
Number of shared co-authors 2
Irbaz Bin Riaz
Mayo Clinic
Career Start Year 2012
Number of shared co-authors 1
Nehme El-Hachem
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 0
Marzia Del Re
University of Pisa
Career Start Year 2010
Number of shared co-authors 4
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 3
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 0
John F Reilly
Goldfinch Bio Inc.
Career Start Year 2007
Number of shared co-authors 2
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 5
Jaclyn LoPiccolo
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 2
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 6
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 3
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 10
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 11
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 7
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 0
Cristina Rodr??guez-Antona
Spanish National Cancer Research Center (CNIO)
Career Start Year 2000
Number of shared co-authors 1
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 2
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 12
Kenneth D Westover
University of Texas Southwestern Medical Center
Career Start Year 1998
Number of shared co-authors 2
Antonio Cubillo
Hospital HM Universitario Sanchinarro
Career Start Year 1997
Number of shared co-authors 5
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 11
Nam Bui
Stanford University
Career Start Year 1996
Number of shared co-authors 3
Sung Tae Kim
Busan Paik Hospital, Inje University
Career Start Year 1996
Number of shared co-authors 5
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 5
Jonathan W Goldman
David Geffen School of Medicine at university of california los angeles
Career Start Year 1991
Number of shared co-authors 5
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 4
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 12
Mark J Ratain
University of Chicago
Career Start Year 1985
Number of shared co-authors 10
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 9
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 14

Collaborators

J??lia Vergara-Alert
Campus de la Universitat Autonoma de Barcelona (UAB)
Co-authored papers 27
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 22
Rodrigo Dienstmann
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 21
Bonaventura Clotet
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 18
José Baselga
Co-authored papers 18
Nuria Izquierdo-Useros
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 16
Shubham Pant
The University of Texas MD Anderson Cancer Center
Co-authored papers 12
Roger Paredes
Hospital Germans Trias i Pujol
Co-authored papers 9
Benjamin Trinité
Co-authored papers 9
Juan Sahuquillo
Vall d'Hebron University Hospital
Co-authored papers 7
Andreas von Deimling
Co-authored papers 6
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Co-authored papers 6
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Co-authored papers 6
Ghazaleh Tabatabai
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Co-authored papers 6
Arie Admon
Co-authored papers 5
Bart L Haagmans
Erasmus Medical Center
Co-authored papers 5
David Capper
Charite University Medicine Berlin
Co-authored papers 5
Hideho Okada
Co-authored papers 5
Patrick Y Wen
Co-authored papers 4
Michael F Berger
Co-authored papers 4
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 4
Xavier Maldonado
Hospital Universitari Vall d'Hebron
Co-authored papers 3
Pablo Avil??s
Departamento de Toxicologia y Farmacologia Preclinica
Co-authored papers 3
Jiabin Tang
The University of MD Anderson Cancer Center
Co-authored papers 3
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 3
Ingrid A Mayer
Vanderbilt University Medical Center
Co-authored papers 3
Marcos Tatagiba
University of Tubingen
Co-authored papers 3
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Co-authored papers 3
Luis Enjuanes
Campus Universidad Autonoma de Madrid
Co-authored papers 3
Ken Chen
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Release 1.2